DEF: Medinotec Sets 2026 Annual Meeting, Board Elections

Medinotec, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on January 20, 2026, to elect five directors and approve its independent auditor.

Summary

• Medinotec, Inc. will hold its 2026 Annual Meeting of Stockholders virtually via video conference on Tuesday, January 20, 2026, at 9:30 a.m. EST.
• Stockholders of record as of December 5, 2025, are eligible to vote. There are 11,755,548 common shares outstanding, with each share entitled to one vote.
• Key proposals include the election of five directors (Gregory Vizirgianakis, Pieter van Niekerk, Stavros G. Vizirgianakis, Joseph P. Dwyer, and Athanasios Spirakis) and the approval of Mercurius & Associates LLP as the independent registered public accounting firm for the fiscal year ending February 28, 2026.
• The Board recommends a 'FOR' vote for all director nominees and the auditor appointment.
• Voting must be completed by 11:59 p.m. EST on January 19, 2026, via email, mail, or facsimile, as electronic voting during the virtual meeting will not be available.
• The company disclosed related party transactions, including an unsecured loan payable of $940,001 to Minoan Medical Proprietary Limited, an entity controlled by CEO Dr. Gregory Vizirgianakis. This loan decreased by $829,687 during the fiscal year ended February 28, 2025, and incurred $141,748 in interest at a prevailing prime lending rate of 11.00% in South Africa.
• Rent expenses paid to Minoan Capital Proprietary Limited, also controlled by Dr. Gregory Vizirgianakis, increased to $51,759 for the fiscal year ended February 28, 2025, from $32,142 in the prior fiscal year.
• Executive compensation for CEO Gregory Vizirgianakis and CFO Pieter van Niekerk was $6,597 and $3,958 respectively for both fiscal years 2025 and 2024, categorized as 'All Other Compensation.' The company noted that officer compensation depends on the availability of cash resources.
• Directors and executive officers collectively beneficially own 9,914,396 shares, representing 84.3% of the company's common stock as of December 5, 2025.
• The company dismissed BDO South Africa Inc. and engaged Mercurius & Associates LLP as its independent registered public accounting firm on July 8, 2024.

Sentiment

Score: 5

Explanation: The filing is neutral as it primarily serves as a procedural proxy statement for an annual meeting. It contains standard corporate governance information, but also highlights significant related party transactions and very low executive compensation, which could be viewed with caution by investors. The high insider ownership is a double-edged sword, indicating alignment but also potential for limited minority shareholder influence. No major positive or negative operational news is presented.

Positives

• The company has a structured plan for its annual meeting and corporate governance, including the election of directors and auditor approval, demonstrating adherence to regulatory requirements.
• An Audit Committee is established with a financial expert (Joseph P. Dwyer) and two independent directors (Joseph P. Dwyer and Athanasios Spirakis), enhancing financial oversight and compliance.
• A Code of Business Conduct and Ethics was adopted on June 21, 2023, applicable to all personnel, which strengthens the ethical framework.
• The related party loan from Minoan Medical Proprietary Limited decreased by $829,687 during FY2025, potentially indicating improved cash flow or active debt management.
• The company asserts that related party rent transactions are market-related, supported by market research with a registered property agent, aiming for fair dealings.

Negatives

• Executive compensation is notably low ($6,597 for CEO, $3,958 for CFO in FY2025 and FY2024), with compensation dependent on cash resources, which could pose challenges for executive retention and talent attraction.
• A significant portion of the company's shares (84.3%) is beneficially owned by directors and executive officers, potentially limiting the influence of minority shareholders.
• The company relies on related party loans for working capital and capital expenditure expansions, such as the $940,001 loan from Minoan Medical, which may indicate a dependence on insider funding rather than diversified capital sources.
• The change in independent registered public accounting firm from BDO South Africa Inc. to Mercurius & Associates LLP on July 8, 2024, while not inherently negative, lacks specific explanation in the filing, which could raise questions.

Risks

• Reliance on related party financing: The company has an unsecured loan of $940,001 from Minoan Medical Proprietary Limited, controlled by the CEO, used for working capital and capex. This reliance could pose risks if the related party's financial situation changes or if terms are not consistently at arm's length.
• Low executive compensation: The company's decision to compensate officers based on cash resources may hinder its ability to attract and retain highly qualified executive talent if cash flow is constrained.
• Concentrated ownership: Directors and executive officers collectively own 84.3% of the common stock, which could lead to decisions that primarily benefit controlling shareholders and potentially limit the influence or interests of minority stockholders.
• Virtual-only annual meeting with no in-meeting voting: Stockholders cannot vote electronically during the virtual meeting, requiring advance submission, which might reduce participation or disenfranchise some investors.
• Potential for conflicts of interest: Significant related party transactions, including rent payments and loans to entities controlled by the CEO, could present potential conflicts of interest, even if the company states they are market-related.

Future Outlook

The filing primarily focuses on corporate governance matters for the upcoming annual meeting and does not provide specific forward-looking statements or financial guidance regarding future performance, revenue, or strategic initiatives. It mentions the company reserves the right to provide executive compensation in the future based on cash resources.

Management Comments

• Our decision to compensate officers depends on the availability of our cash resources with respect to the need for cash to further business purposes.
• The Company has no reason to believe that any of the nominees named below will be unable to serve as a director if elected.
• Rent is comparable to rent charged for similar properties in the same relative area. The Consolidated entities do market research of a Minimum and a Maximum rental value within the area at every renewal of the rental agreement to ensure this is market related, this exercise is undertaken together with a registered property agent who has the appropriate knowledge of the area.
• The Prime rate is therefore an arms length transaction and justifiable rate that can be applied to a loan within the borders of the Republic of South Africa.

Industry Context

This filing is a standard definitive proxy statement, primarily detailing corporate governance, director elections, and auditor appointments. It does not provide specific operational or strategic updates that would allow for a detailed analysis of its relation to broader industry trends or competitors. The company operates in the medical device field, as indicated by the backgrounds of its directors, but the filing itself does not offer insights into its competitive position or market dynamics. The related party transactions and low executive compensation might suggest a smaller, developing company in the medical device sector, potentially relying on internal funding and a lean operational structure.

Comparison to Industry Standards

• Executive Compensation: The executive compensation levels ($6,597 for CEO, $3,958 for CFO) are significantly below industry standards for publicly traded companies, especially in the medical device sector. CEOs of comparable small-cap medical device companies typically earn hundreds of thousands to millions of dollars annually in salary, bonus, and equity. This low compensation, coupled with the statement that it depends on cash resources, suggests the company is either in a very early stage, has severe cash constraints, or executives are compensated through other means not disclosed as direct salary/bonus.
• Corporate Governance: The establishment of an Audit Committee with a financial expert and independent directors aligns with standard corporate governance practices for public companies, particularly those listed on exchanges like NASDAQ (as referenced by NASDAQ Rule 5605). However, the full board serving as the nominating committee is less common for larger public companies, which often have a dedicated nominating and governance committee.
• Related Party Transactions: While related party transactions are not uncommon, the extent of reliance on loans from entities controlled by the CEO (e.g., $940,001 loan from Minoan Medical) and rent payments to another CEO-controlled entity (Minoan Capital) is higher than typically seen in mature, well-capitalized public companies. While the company states these are market-related, such arrangements can raise questions about potential conflicts of interest and financial independence compared to companies with more diversified funding sources.
• Shareholder Concentration: The 84.3% beneficial ownership by directors and executive officers is a very high concentration, far exceeding typical institutional or retail ownership in most publicly traded companies. This level of control is more characteristic of private companies or those recently gone public, and it significantly reduces the influence of minority shareholders compared to industry benchmarks.

Corporate Governance

Related Party Transactions

• Loan payable of $940,001 from Minoan Medical Proprietary Limited (controlled by CEO Dr. Gregory Vizirgianakis) to fund working capital and capex expansions of DISA Medinotec. This loan decreased by $829,687 in FY2025 and carries interest at the South African prime lending rate (11.00% on Feb 28, 2025), with $141,748 in interest charged for FY2025.
• Rental expenses of $51,759 for FY2025 (up from $32,142 in FY2024) paid by DISA Medinotec Proprietary Limited to Minoan Capital Proprietary Limited, which is 100% owned by CEO Dr. Gregory Vizirgianakis. The company states rent is comparable to market rates.
• Medinotec Capital Proprietary Limited (African holding company) has a related party loan payable to Minoan Capital.
• DISA Medinotec Proprietary Limited (African operating and manufacturing company) has a related party loan with Minoan Medical and operational income and expenses with Minoan Medical.
• Gregory Vizirgianakis and Stavros Vizirgianakis (brothers) are the primary controlling shareholders of Medinotec Incorporated Nevada.
• Pieter van Niekerk is a minority shareholder in Medinotec Inc.

Stakeholder Impact

• Shareholders: Will vote on key governance matters (directors, auditor). High insider ownership (84.3%) means minority shareholders have limited influence. Related party transactions and low executive compensation could be areas of concern or scrutiny.
• Employees: The Code of Ethics applies to all employees, promoting ethical conduct. No direct impact on employees (e.g., layoffs, new benefits) is mentioned.
• Customers/Suppliers: No direct impact mentioned. The company's operations in medical devices imply a customer base in healthcare, but the filing doesn't detail customer or supplier relationships.
• Creditors: The significant related party loan from Minoan Medical ($940,001) and its repayment progress ($829,687 decrease in FY2025) are relevant to creditors, indicating the company's debt structure and ability to manage obligations, albeit to an insider.

Next Steps

• Stockholders to vote on the election of five directors by January 19, 2026.
• Stockholders to vote on the approval of Mercurius & Associates LLP as the independent registered public accounting firm for fiscal year ending February 28, 2026, by January 19, 2026.
• The 2026 Annual Meeting of Stockholders will be held virtually on January 20, 2026.
• The Audit Committee will consider selecting another registered public accounting firm if Mercurius & Associates LLP is not approved.
• Stockholders can submit proposals for inclusion in the 2026 proxy statement by September 13, 2026.
• Stockholders can present proposals or director nominations directly at the 2026 Annual Meeting between November 21, 2026, and December 21, 2026.

Key Dates

Recommendation

This filing is a standard definitive proxy statement, primarily outlining the agenda for the upcoming annual meeting, including director elections and auditor approval. It does not contain new operational results, strategic shifts, or significant financial updates that would fundamentally alter the investment thesis. While the disclosures reveal a high degree of insider ownership (84.3%) and notable related party transactions, these are structural aspects of the company rather than new catalysts. The very low executive compensation and reliance on related party loans for working capital might raise questions about the company's financial maturity or cash flow, but these are not new revelations. Therefore, for existing investors, maintaining a 'hold' position is prudent until more substantive financial or operational news becomes available. For new investors, there isn't enough information in this procedural filing to make a strong 'buy' or 'sell' recommendation.

Keywords

Medinotec, Proxy Statement, Annual Meeting, Corporate Governance, Director Election, Auditor Approval, Related Party Transactions, Executive Compensation, Shareholder Vote, SEC Filing, MDNC, Medical Devices